Quarterly report pursuant to Section 13 or 15(d)

Organization and Principal Activities

Organization and Principal Activities
3 Months Ended
Mar. 31, 2022
Disclosure Text Block [Abstract]  
Organization and Principal Activities

1. Organization and Principal Activities

Description of Business

Sutro Biopharma, Inc. (the “Company”), is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF® and its site-specific conjugation platform, XpressCF+® to create a broad variety of optimally designed, next-generation protein therapeutics, initially for cancer. The Company was incorporated on April 21, 2003 and is headquartered in South San Francisco, California.

The Company operates in one business segment, the development of biopharmaceutical products.


The Company has incurred significant losses and has negative cash flows from operations. As of March 31, 2022, the Company had an accumulated deficit of $372.5 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development and other operational activities.

As of March 31, 2022, the Company had unrestricted cash, cash equivalents and marketable securities of $192.1 million, which is available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and to support its operations.

The Company believes that its unrestricted cash, cash equivalents and marketable securities as of March 31, 2022 will enable the Company to maintain its operations for a period of at least 12 months following the filing date of its financial statements.